ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05405595. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination With Pembrolizumab (Anti PD-1 Antibody) in Patients With Advanced/Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05405595
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Adagene Inc
- Industry
- Enrollment
- 186 participants
Conditions and interventions
Conditions
Interventions
- ADG126 Drug
- Pembrolizumab (KEYTRUDA®) Drug
- Standard of Care (Trifluridine/Tipiracil-Bevacizumab) Drug
- Standard of care (Fruquintinib) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 14, 2022
- Primary completion
- Oct 30, 2026
- Completion
- Apr 29, 2027
- Last update posted
- Jan 6, 2026
2022 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Honor Health Research Institute | Scottsdale | Arizona | 85251 | Recruiting |
| City of Hope National Medical Center | Duarte | California | 91010 | Recruiting |
| City of Hope Orange County | Irvine | California | 92618 | Recruiting |
| Florida cancer specialist/Sarah Cannon Research Institute | Sarasota | Florida | 34232 | Active, not recruiting |
| The Cleveland Clinic | Cleveland | Ohio | 44195-0001 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05405595, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05405595 live on ClinicalTrials.gov.